For more than two decades, the intravenous administration of high doses of IgG pooled from the plasma of healthy donors (immune globulin therapy, also known as 'IVIG') has benefited patients with a variety of autoimmune disorders. A potential therapeutic role of IVIG in the prevention of thrombosis and of miscarriages in antiphospholipid syndrome (APS) has been postulated. Multicenter randomized controlled trials attempted to define the role of IVIG in preventing pregnancy complications in APS indicate that simple anticoagulation could not be completely satisfactory, and certain patient subgroups might take advantage of IVIG therapy alone or in combination with hepari
TRIOLO G, FERRANTE A, ACCARDO-PALUMBO A, CICCIA F, CADELO M, CASTELLI A, et al. (2004). IVIG in APS pregnancy. LUPUS, 13(9), 731-735 [10.1191/0961203304lu2011oa].
IVIG in APS pregnancy
TRIOLO, Giovanni;CICCIA, Francesco;CADELO, Marcello;CASTELLI, Antonio;PERINO, Antonino;LICATA, Giuseppe
2004-01-01
Abstract
For more than two decades, the intravenous administration of high doses of IgG pooled from the plasma of healthy donors (immune globulin therapy, also known as 'IVIG') has benefited patients with a variety of autoimmune disorders. A potential therapeutic role of IVIG in the prevention of thrombosis and of miscarriages in antiphospholipid syndrome (APS) has been postulated. Multicenter randomized controlled trials attempted to define the role of IVIG in preventing pregnancy complications in APS indicate that simple anticoagulation could not be completely satisfactory, and certain patient subgroups might take advantage of IVIG therapy alone or in combination with hepari
| File | Dimensione | Formato | |
|---|---|---|---|
|
IVIG in APS pregnancy.pdf
Solo gestori archvio
Dimensione
199.25 kB
Formato
Adobe PDF
|
199.25 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
